225Ac-DOTAZOL is a DOTA Zoledronic acid derivative suitable for alphatherapy in complement to 177Lu-radiotherapy. 225Ac-DOTAZOL is a potent bisphosphonate for alpharadiotherapy of bone diseases tested in prostate cancer patients.
The first preclinical data were published in 2018. 225Ac-DOTAZOL confirms the well-known pharmacology of DOTAZOL derivatives (68Ga and 177Lu) in preclinical evaluations.
Radiotherapeutics
Ac-225-DOTAZOL
- Target/Mechanism
- Bones
- Carrier/Ligand
- n/a
- Radiation Type
- alpha (α)